Your browser doesn't support javascript.
loading
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).
Hua, Xin; Bi, Xi-Wen; Zhao, Jian-Li; Shi, Yan-Xia; Lin, Ying; Wu, Zhi-Yong; Zhang, Yuan-Qi; Zhang, Le-Hong; Zhang, An-Qing; Huang, Heng; Liu, Xin-Mei; Xu, Fei; Guo, Ying; Xia, Wen; Hong, Ruo-Xi; Jiang, Kui-Kui; Xue, Cong; An, Xin; Zhong, Yong-Yi; Wang, Shu-Sen; Huang, Jia-Jia; Yuan, Zhong-Yu.
Affiliation
  • Hua X; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Bi XW; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Zhao JL; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Shi YX; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Lin Y; Thyroid and Breast Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Wu ZY; Department of Oncology Surgery, Diagnosis and Treatment Center of Breast Diseases, Affiliated Shantou Hospital, Sun Yat-sen University, Shantou, China.
  • Zhang YQ; Department of Vascular Surgery, Affiliated Hospital of Guangdong Medical College, Zhanjiang, China.
  • Zhang LH; Department of Breast Oncology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Zhang AQ; Department of Breast Oncology, Maternal and Child Health Care Hospital of Guangdong Province, Guangzhou, China.
  • Huang H; Department of Breast Oncology, Lianjiang Pepole's Hospital, Lianjiang, China.
  • Liu XM; Department of Breast Oncology, Haikou People's Hospital, Haikou, China.
  • Xu F; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Guo Y; Department of Good Clinical Practice, the State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Xia W; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Hong RX; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Jiang KK; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Xue C; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • An X; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Zhong YY; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Wang SS; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Huang JJ; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Yuan ZY; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Clin Cancer Res ; 28(4): 637-645, 2022 02 15.
Article in En | MEDLINE | ID: mdl-34810217
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Clinical_trials / Risk_factors_studies Limits: Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: China Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Clinical_trials / Risk_factors_studies Limits: Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: China Country of publication: Estados Unidos